Lipocine Inc

STU:2VT0 (USA)  
€ 3.94 (0%) Apr 25
At Loss
P/B:
1.16
Market Cap:
€ 22.74M ($ 24.37M)
Enterprise V:
€ -15.13M ($ -16.21M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:

Business Description

Description
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.89
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -8.16
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
12-1 Month Momentum % -8.66

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.69
Quick Ratio 8.69
Cash Ratio 8.37
Days Payable 59.7

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.9